267
Participants
Start Date
May 31, 2011
Primary Completion Date
March 31, 2012
Study Completion Date
June 30, 2012
2304 Eye Drops High Dose
2304 Eye Drops High Dose self-administered in the study eye during the treatment period
2304 Eye Drops Low Dose
2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
Placebo Eye Drops
Placebo Eye Drops self-administered in the study eye during the treatment period
Center 1115, Phoenix
Center 1116, Phoenix
Center 1108, Fort Myers
Center 1106, Chicago
Center 1105, Indianapolis
Center 1101, Boston
Center 1109, Boston
Center 1111, Boston
Center 1114, Traverse
Center 1112, Toms River
Center 1107, Lynbrook
Center 1110, Pittburgh
Center 1104, Nashville
Center 1103, San Antonio
Center 2003, Chatswood
Center 2002, Melbourne
Center 2004, Murdoch
Center 2001, Sydney
Center 1302, Antwerp
Center 1301, Brussels
Center 1303, Wilrijk
Center 1704, Brno
Center 1701, Hradec Králové
Center 1703, Ostrava
Center 1702, Prague
Center 1705, Prague
Center 1706, Zlín
Center 1401, Dijon
Center 1402, Marseille
Center 1405, Nantes
Center 1403, Paris
Center 1404, Paris
Center 1504, Ahaus
Center 1502, Darmstadt
Center 1503, Freiburg im Breisgau
Center 1501, Karlsruhe
Center 1506, Leipzig
Center 1507, Münster
Center 1505, Saarbrücken
Center 1907, Afula
Center 1906, Beer Yakov
Center 1909, Beersheba
Center 1903, Jerusalem
Center 1908, Kfar Saba
Center 1902, Petah Tikva
Center 1901, Rehovot
Center 1904, Tel Aviv
Center 1905, Tel Litwinsky
Center 1604, Florence
Center 1601, Milan
Center 1607, Milan
Center 1610, Rome
Center 1606, Saronno
Center 1608, Udine
Center 1609, Verona
Center1801, Bydgoszcz
Center 1802, Gdansk
Center 1205, Alicante
Center 1201, Barcelona
Center 1202, Barcelona
Center 1204, Oviedo
Center 1206, Santiago de Compostela
Center 1208, Seville
Center 1209, Valencia
Center 1203, Valladolid
Lead Sponsor
Fovea Pharmaceuticals SA
INDUSTRY